Yue Dai Selected Research

madecassic acid

1/2022	Madecassic acid alleviates colitis-associated colorectal cancer by blocking the recruitment of myeloid-derived suppressor cells via the inhibition of IL-17 expression in γδT17 cells.
12/2020	Regulation of gut microbiota substantially contributes to the induction of intestinal Treg cells and consequent anti-arthritis effect of madecassoside.
1/2020	Inhibition of the activation of γδT17 cells through PPARγ-PTEN/Akt/GSK3β/NFAT pathway contributes to the anti-colitis effect of madecassic acid.
1/2017	Madecassic acid, the contributor to the anti-colitis effect of madecassoside, enhances the shift of Th17 toward Treg cells via the PPARγ/AMPK/ACC1 pathway.
12/2014	A LC-ESI-MS method for the simultaneous determination of madecassoside and its metabolite madecassic acid in rat plasma: comparison pharmacokinetics in normal and collagen-induced arthritic rats.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yue Dai Research Topics

Disease

32	Arthritis (Polyarthritis) 10/2021 - 05/2007
25	Experimental Arthritis 01/2022 - 04/2009
22	Inflammation (Inflammations) 04/2022 - 09/2002
20	Rheumatoid Arthritis 09/2022 - 05/2007
20	Colitis 08/2022 - 12/2014
18	Neoplasms (Cancer) 01/2022 - 04/2008
9	Body Weight (Weight, Body) 03/2015 - 05/2007
7	Pulmonary Fibrosis (Fibrosing Alveolitis) 01/2022 - 10/2013
7	Hypertension (High Blood Pressure) 01/2022 - 07/2010
7	Fibrosis (Cirrhosis) 03/2021 - 06/2013
7	Hypersensitivity (Allergy) 01/2018 - 03/2004
6	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 08/2022 - 08/2015
6	Infections 01/2021 - 12/2014
4	Obesity 01/2022 - 08/2010
4	Hypoxia (Hypoxemia) 01/2022 - 04/2016
4	Keloid 08/2017 - 08/2012
4	Cicatrix (Scar) 11/2013 - 11/2008
4	Sepsis (Septicemia) 07/2012 - 02/2009
3	Asthma (Bronchial Asthma) 04/2022 - 01/2012
3	Autoimmune Diseases (Autoimmune Disease) 01/2022 - 01/2017
3	Cardiovascular Diseases (Cardiovascular Disease) 05/2021 - 09/2018
3	Stroke (Strokes) 01/2021 - 03/2019
3	Ureteral Obstruction 01/2021 - 06/2013
3	Ulcerative Colitis 01/2020 - 12/2015
3	Weight Gain 01/2018 - 08/2010
3	Hepatocellular Carcinoma (Hepatoma) 07/2015 - 11/2011
3	Wounds and Injuries (Trauma) 11/2013 - 06/2008
3	Edema (Dropsy) 10/2013 - 09/2002
3	Overweight 03/2013 - 08/2010
3	Anaphylaxis (Anaphylactic Shock) 01/2005 - 09/2002
2	Paralysis (Palsy) 09/2022 - 01/2017
2	Respiratory Tract Diseases (Respiratory Tract Disease) 04/2022 - 07/2010
2	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2022 - 12/2021
2	Abdominal Obesity 01/2022 - 01/2013
2	Colitis-Associated Neoplasms 01/2022 - 10/2020
2	Prehypertension 01/2022 - 01/2021
2	Atherosclerosis 07/2021 - 01/2021

Drug/Important Bio-Agent (IBA)

14	norisoboldineIBA 01/2022 - 08/2012
13	Dextran SulfateIBA 07/2022 - 12/2014
13	AlkaloidsIBA 01/2022 - 05/2007
11	Pharmaceutical PreparationsIBA 10/2021 - 11/2008
11	madecassosideIBA 12/2020 - 06/2008
9	CollagenIBA 10/2019 - 05/2007
8	TriterpenesIBA 01/2022 - 06/2008
8	Interleukin-6 (Interleukin 6)IBA 01/2021 - 08/2012
8	Aryl Hydrocarbon Receptors (Aryl Hydrocarbon Receptor)IBA 06/2020 - 01/2015
8	SaponinsIBA 03/2015 - 05/2006
7	arctigeninIBA 08/2022 - 12/2014
7	tetrandrineIBA 01/2022 - 11/2015
7	Proteins (Proteins, Gene)FDA Link 01/2021 - 06/2009
6	Interleukin-17 (Interleukin 17)IBA 04/2022 - 05/2015
6	Therapeutic UsesIBA 04/2022 - 04/2010
6	Bleomycin (Blenoxane)FDA LinkGeneric 01/2022 - 10/2013
6	AntigensIBA 01/2021 - 07/2003
6	CytokinesIBA 10/2019 - 04/2008
5	madecassic acidIBA 01/2022 - 12/2014
5	isoquinolineIBA 12/2021 - 03/2013
5	2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amideIBA 01/2021 - 01/2018
5	ScopoletinIBA 07/2015 - 08/2010
4	Fatty Acids (Saturated Fatty Acids)IBA 01/2022 - 10/2020
4	morinIBA 01/2022 - 12/2015
4	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2022 - 01/2013
4	LipopolysaccharidesIBA 01/2021 - 10/2011
4	InflammasomesIBA 10/2020 - 01/2018
4	Antihypertensive Agents (Antihypertensives)IBA 01/2020 - 03/2014
4	sinomenineIBA 09/2018 - 05/2015
4	Interleukin-10 (Interleukin 10)IBA 01/2017 - 03/2015
4	peoniflorinIBA 06/2016 - 10/2011
4	Messenger RNA (mRNA)IBA 12/2015 - 06/2009
4	coumarinIBA 12/2013 - 07/2009
4	Histamine (Histamine Dihydrochloride)FDA Link 05/2013 - 09/2002
4	Sodium Glutamate (Accent)IBA 03/2013 - 08/2010
4	p-Methoxy-N-methylphenethylamineIBA 01/2005 - 09/2002
3	bergeninIBA 04/2022 - 01/2017
3	CurcuminIBA 03/2021 - 05/2015
3	LipidsIBA 01/2021 - 12/2014
3	Uric Acid (Urate)IBA 01/2021 - 08/2010
3	Leucine (L-Leucine)FDA Link 01/2020 - 08/2015
3	BerberineIBA 11/2019 - 01/2017
3	FlavonoidsIBA 11/2018 - 01/2005
3	Peroxidase (Myeloperoxidase)IBA 01/2018 - 10/2009
3	Collagen Type II (Type II Collagen)IBA 12/2015 - 05/2007
3	Phosphotransferases (Kinase)IBA 01/2015 - 08/2012
2	NAD (NADH)IBA 08/2022 - 01/2018
2	EnzymesIBA 04/2022 - 01/2022
2	2-chloro-5-nitrobenzanilideIBA 04/2022 - 01/2013
2	Triglycerides (Triacylglycerol)IBA 01/2022 - 12/2014
2	CholesterolIBA 01/2022 - 12/2014
2	Polysaccharides (Glycans)IBA 01/2022 - 01/2011
2	SaltsIBA 01/2022 - 09/2014
2	Diclofenac (SR 38)FDA LinkGeneric 10/2021 - 04/2010
2	Silicon Dioxide (Silica)FDA LinkGeneric 07/2021 - 01/2021
2	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 03/2021 - 04/2016

Therapy/Procedure

15	Oral Administration 01/2022 - 06/2008
9	Chinese Traditional Medicine (Traditional Chinese Medicine) 09/2022 - 07/2009
9	Therapeutics 07/2021 - 08/2012
3	Intraperitoneal Injections 07/2022 - 01/2011
3	Ligation 02/2011 - 02/2009
3	Punctures 02/2011 - 02/2009
2	Precision Medicine 07/2021 - 08/2016